Polymeric nanoparticles for delivery in the gastro-intestinal tract

Nanoparticulates as Drug Carriers

Volumn , Issue , 2006, Pages 609-648

  Bhavsar, Mayank D ^a   Shenoy, Dinesh B ^a   Amiji, Mansoor M ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GASTROINTESTINAL TRACT; POLYMERIC NANOPARTICLES;

EID: 34248642132     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1142/9781860949074_0026     Document Type: Chapter

References (143)

1. Wilson K and Waugh A (1996) Anatomy and Physiology in Health and Illness. Churchill Livingstone: New York.
2. Tortora G and Anagnostakos N (1978) Principles of Anatomy and Physiology. Harper and Row: New York.
3. Tate P, Seeley R and Stephens T (1994) Understanding the Human Body. Mosby: St. Louis.
4. Solomon E (1992) Introduction to Human Anatomy and Physiology. W. B. Saunders Company, Philadelphia.
5. McClintic JR (1980) Basic Anatomy and Physiology of the Human Body. John Wiley and Sons: New York.
6. Ganong W (2003) Review of Medical Physiology. Appleton and Lange: Norwalk, CT.
7. Shojaei A (1998) Buccal mucosa as a route for systemic drug delivery: A review. J Pharm Pharma Sci 1:15-30.
8. Zhang H, Zhang J and Streisand JB (2002) Oral mucosal drug delivery: Clinical pharmacokinetics and therapeutic applications. Clin Pharmacokinet 41:661-680.
9. Collins L and Dawes C (1987) The surface area of the adult human mouth and thichness of the salivary film covering the teeth and oral mucosa. J Dent Res 66:1300-1302.
10. Harris D and Robinson J (1992) Drug delivery via the mucous membranes of the oral cavity. J Pharm Sci 81:1-10.
11. Sakuma S, Hayashi M and Akashi M (2001) Design of nanoparticles composed of graft copolymers for oral peptide delivery. Adv Drug Del Rev 47:21-37.
12. Gandhi RR, J (1994) Oral cavity as a site for bioadhesive drug delivery. Adv Drug Del Rev 13:43-74.
13. Florence AT (1993) Particulate delivery: The challenge of the oral route. Drugs Pharm Sci 61:65-107.
14. Jung T, Kamm W, Breitenbach A, Kaiserling E, Xiao JX and Kissel T (2000) Biodegradable nanoparticles for oral delivery of peptides: Is there a role for polymers to affect mucosal uptake? Eur J Pharm Biopharm 50:147-160.
15. Friend DR (2004) Drug delivery to the small intestine. Curr Gastroenterol Rep 6:371-376.
16. Florence AT, Hussain N and Jani P (1995) Nanoparticles as carriers for oral peptide absorption: Studies on particle uptake and fate. J Control Rel 36:39-46.
17. Lamprecht A, Schafer U and Lehr CM (2001) Size-dependent bioadhesion of micro- and nanoparticulate carriers to the inflamed colonic mucosa. Pharm Res 18:788-793.
18. Lamprecht A, Ubrich N, Yamamoto H, Schafer U, Takeuchi H, Maincent P, Kawashima Y and Lehr CM (2001) Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease. J Pharmacol Exp Ther 299:775-781.
19. Popescu C and Onyuksel H (2004) Biodegradable nanoparticles incorporating highly hydrophilic positively charged drugs US Patent No. 20040247683.
20. Tobio M, Sanchez A, Vila A, Soriano II, Evora C, Vila-Jato JL and Alonso MJ (2000) The role of PEG on the stability in digestive fluids and in vivo fate of PEG-PLA nanoparticles following oral administration. Coll Surf B Biointerf 18:315-323.
21. Florence AT (2004) Issues in oral nanoparticle drug carrier uptake and targeting. J Drug Targ 12:65-70.
22. Dai J, Nagai T, Wang X, Zhang T, Meng M and Zhang Q (2004) pH-sensitive nanoparticles for improving the oral bioavailability of cyclosporine A. Int J Pharm 280:229-240.
23. Takeuchi H, Yamamoto H and Kawashima Y (2001) Mucoadhesive nanoparticulate systems for peptide drug delivery. Adv Drug Del Rev 47:39-54.
24. Vemuri S and Rhodes CT (1995) Preparation and characterization of liposomes as therapeutic delivery systems: A review. Pharm Acta Helv 70:95-111.
25. Uchegbu IF and Vyas SP (1998) Non-ionic surfactant based vesicles (niosomes) in drug delivery. Int J Pharm 172:33-70.
26. Douglas SJ, Davis SS and Ilium L (1987) Nanoparticles in drug delivery. Crit Rev Ther Drug Carr Syst 3:233-261.
27. Boas U and Heegaard PM (2004) Dendrimers in drug research. Chem Soc Rev 33:43-63.
28. Rabinow BE (2004) Nanosuspensions in drug delivery. Nat Rev Drug Discov 3:785-796.
29. Sonneville-Aubrun O, Simonnet JT and L’Alloret F (2004) Nanoemulsions: A new vehicle for skincare products. Adv Coll Interf Sci 108-109:145-149.
30. Tenjarla S (1999) Microemulsions: An overview and pharmaceutical applications. Crit Rev Ther Drug Carr Syst 16:461-521.
31. Kataoka K, Harada A and Nagasaki Y (2001) Block copolymer micelles for drug delivery: Design, characterization and biological significance. Adv Drug Del Rev 47:113-131.
32. Solaro R (2002) Nanostructured polymeric systems in targeted release of proteic drugs and in tissue engineering China-EU Forum on Nanosized Technology. China-EU Forum, Beijng.
33. Quintanar-Guerrero DA, E; Fessi, H; Doelker, E (1998) Preparation techniques and mechanisms of formation of biodegradable nanoparticles from preformed polymers. Drug Dev Ind Pharm 24:1113-1128.
34. Barratt G (2003) Colloidal drug carriers: Achievements and perspectives. Cell Mol Life Sci 60:21-37.
35. Soppimath KS, Aminabhavi TM, Kulkarni AR and Rudzinski WE (2001) Biodegradable polymeric nanoparticles as drug delivery devices. J Control Rel 70:1-20.
36. Kreuter J (2001) Nanoparticulate systems for brain delivery of drugs. Adv Drug Del Rev 47:65-81.
37. Alonso MJ (2001) Polymeric nanoparticles: New systems for improving ocular bioavailability of drugs. Arch Soc Esp Oftalmol 76:453-454.
38. Barratt G (2003) Colloidal drug carriers: Achievements and perspectives. Cell Mol Life Sci 60:21-37.
39. Kreuter J (1996) Nanoparticles and microparticles for drug and vaccine delivery. J Anat 189:503-505.
40. Speiser PP (1991) Nanoparticles and liposomes: A state of the art. Meth Find Exp Clin Pharmacol 13:337-342.
41. Panyam J and Labhasetwar V (2003) Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Del Rev 55:329-347.
42. Otsuka H, Nagasaki Y and Kataoka K (2003) PEGylated nanoparticles for biological and pharmaceutical applications. Adv Drug Del Rev 55:403-49.
43. Emerich DF and Thanos CG (2003) Nanotechnology and medicine. Exp Opin Biol Ther 3:655-663.
44. Lockman PR, Mumper RJ, Khan MA and Allen DD (2002) Nanoparticle technology for drug delivery across the blood-brain barrier. Drug Dev Ind Pharm 28:1-13.
45. Brigger I, Dubernet C and Couvreur P (2002) Nanoparticles in cancer therapy and diagnosis. Adv Drug Del Rev 54:631-651.
46. Moghimi SM, Hunter AC and Murray JC (2001) Long-circulating and target-specific nanoparticles: Theory to practice. Pharmacol Rev 53:283-318.
47. Lambert G, Fattal E and Couvreur P (2001) Nanoparticulate systems for the delivery of antisense oligonucleotides. Adv Drug Del. Rev 47:99-112.
48. Janes KA, Calvo P and Alonso MJ (2001) Polysaccharide colloidal particles as delivery systems for macromolecules. Adv Drug Del Rev 47:83-97.
49. Benns JM and Kim SW (2000) Tailoring new gene delivery designs for specific targets. J Drug Targ 8:1-12.
50. Tan Y, Whitmore M, Li S, Frederik P and Huang L (2002) LPD nanoparticles-novel non viral vector for efficient gene delivery. Meth Mol Med 69:73-81.
51. Vijayanathan V, Thomas T and Thomas TJ (2002) DNA nanoparticles and development of DNA delivery vehicles for gene therapy. Biochemistry 41:14085-14094.
52. Cui Z and Mumper RJ (2003) Microparticles and nanoparticles as delivery systems for DNA vaccines. Crit Rev Ther Drug Carr Syst 20:103-137.
53. Vila A, Sanchez A, Evora C, Soriano I, Vila Jato JL and Alonso MJ (2004) PEG-PLA nanoparticles as carriers for nasal vaccine delivery. J Aerosol Med 17:174-185.
54. Prego C, Garcia M, Torres D and Alonso MJ (2005) Transmucosal macromolecular drug delivery. J Control Rel 101:151-162.
55. Videira MA, Botelho MF, Santos AC, Gouveia LF, de Lima JJ and Almeida AJ (2002) Lymphatic uptake of pulmonary delivered radiolabelled solid lipid nanoparticles. J Drug Targ 10:607-613.
56. Shim J, Seok Kang H, Park WS, Han SH, Kim J and Chang IS (2004) Transdermal delivery of mixnoxidil with block copolymer nanoparticles. J Control Rel 97:477-484.
57. General S and Thunemann AF (2001) pH-sensitive nanoparticles of poly (amino acid) dodecanoate complexes. Int J Pharm 230:11-24.
58. Mansouri S, Lavigne P, Corsi K, Benderdour M, Beaumont E and Fernandes JC (2004) Chitosan-DNA nanoparticles as non-viral vectors in gene therapy: Strategies to improve transfection efficacy. Eur J Pharm Biopharm 57:1-8.
59. Thunemann AF and General S (2001) Nanoparticles of a polyelectrolyte-fatty acid complex: Carriers for Q10 and triiodothyronine. J Control Rel 75:237-247.
60. General S, Rudloff J and Thunemann AF (2002) Hollow nanoparticles via stepwise complexation and selective decomplexation of poly (ethylene imine). Chem Commun 5:534-535.
61. Akiyoshi K, Kobayashi S, Shichibe S, Mix D, Baudys M, Kim SW and Sunamoto J (1998) Self-assembled hydrogel nanoparticle of cholesterol-bearing pullulan as a carrier of protein drugs: Complexation and stabilization of insulin. J Control Rel 54:313-320.
62. Sang Yoo H and Gwan Park T (2004) Biodegradable nanoparticles containing proteinfatty acid complexes for oral delivery of salmon calcitonin. J Pharm Sci 93:488-495.
63. Du J, Zhang S, Sun R, Zhang LF, Xiong CD and Peng YX (2005) Novel polyelectrolyte carboxymethyl konjac glucomannan-chitosan nanoparticles for drug delivery. II. Release of albumin in vitro. J Biomed Mater Res B Appl Biomater 72:299-304.
64. Sun YP, Meziani MJ, Pathak P and Qu L (2005) Polymeric nanoparticles from rapid expansion of supercritical fluid solution. Chemistry 11:1366-1373.
65. Young TJ, Johnson KP, Pace GW and Mishra AK (2004) Phospholipid-stabilized nanoparticles of cyclosporine A by rapid expansion from supercritical to aqueous solution. AAPS PharmSciTech 5:E11.
66. Subramaniam B, Rajewski RA and Snavely K (1997) Pharmaceutical processing with supercritical carbon dioxide. J Pharm Sci 86:885-890.
67. Gokhale AA, Khushi B, Dave RN and Pfeffer R (2005) Formation of polymer nanoparticles in supercritical fluid jets. Nanotech (May).
68. Couvreur P (1988) Polyalkylcyanoacrylates as colloidal drug carriers. Crit Rev Ther Drug Carr Syst 5:1-20.
69. Brannon-Peppas L (1997) Polymers in controlled drug delivery. Med Plastics Biomater Mag, 34.
70. Kumar MNV (2000) Nano and microparticles as controlled drug delivery devices J Pharm Pharmaceut Sci 3:234-258.
71. McCarron PA, Donnelly RF, Canning PE, McGovern JG and Jones DS (2004) Bioadhesive, non-drug-loaded nanoparticles as modulators of candidal adherence to buccal epithelial cells: A potentially novel prophylaxis for candidosis. Biomaterials 25:2399-2407.
72. Ch’ng HS, Park H, Kelly P and Robinson JR (1985) Bioadhesive polymers as platforms for oral controlled drug delivery II: Synthesis and evaluation of some swelling, water-insoluble bioadhesive polymers. J Pharm Sci 74:399-405.
73. Leung SR, J. (1990) Polymer structure features contributing to mucoadhesion: II. J Control Rel 12:187-194.
74. Sanzgiri Y, Topp E, Benedetti L and Stella V (1994) Evaluation of mucoadhesive properties of hyaluronic acid benzyl esters. Int J Pharm 107:91-97.
75. Luessen HL, Verhoef JC, Borchard G, Lehr CM, de Boer AG and Junginger HE (1995) Mucoadhesive polymers in peroral peptide drug delivery. II. Carbomer and polycar-bophil are potent inhibitors of the intestinal proteolytic enzyme trypsin. Pharm Res 12:1293-1298.
76. Park KR, J. (1984) Bioadhesive polymers as platforms for oral-controlled drug delivery: Method to study bioadhesion. Int J Pharm 19:107-127.
77. Nagai TM, Y. (1993) Buccal delivery systems using hydrogels. Adv Drug Del Rev 11:179-191.
78. Taylan B, Yilmaz C, Guven O, Kes S and Hincal A (1996) Design evaluation of sustained-release and buccal adhesive propranolol hydrochloride tablets. J Control Rel 38:11-20.
79. Leung S and Robinson J (1988) The contribution of anionic polymer structural features to mucoadhesion. J Control Rel 5:223-231.
80. Venugopalan P, Sapre A, Venkatesan N and Vyas SP (2001) Pelleted bioadhesive polymeric nanoparticles for buccal delivery of insulin: Preparation and characterization. Pharmazie 56:217-219.
81. Gandhi R and Robinson J (1988) Bioadhesion in drug delivery. Indian J Pharm Sci 50:145-152.
82. Neuberger W (2004) Treatment of periodontal disease with photosensitizers, Int Patent WO 2004/024080 A2.
83. Chowdhary RK and Dolphin D (2002) Supports for photosensitizer formulations, US Patent No. 20020061330.
84. Hejazi R and Amiji M (2002) Stomach-specific anti-H. pylori therapy. I: Preparation and characterization of tetracyline-loaded chitosan microspheres. Int J Pharm 235:87-94.
85. Umamaheshwari RB, Ramteke S and Jain NK (2004) Anti-Helicobacter pylori effect of mucoadhesive nanoparticles bearing amoxicillin in experimental gerbils model. AAPS PharmSciTech 5:1-9.
86. Ezpeleta I, Arangoa MA, Irache JM, Stainmesse S, Chabenat C, Popineau Y and Orecchioni AM (1999) Preparation of Ulex europaeus lectin-gliadin nanoparticle conjugates and their interaction with gastrointestinal mucus. Int J Pharm 191:25-32.
87. Dawson M, Krauland E, Wirtz D and Hanes J (2004) Transport of polymeric nanoparticle gene carriers in gastric mucus. Biotechnol Prog 20:851-857.
88. Gao H, Wang JY, Shen XZ, Deng YH and Zhang W (2004) Preparation of magnetic polybutylcyanoacrylate nanospheres encapsulated with aclacinomycin A and its effect on gastric tumor. World J Gastroenterol 10:2010-2013.
89. Ponchel G and Irache J (1998) Specific and non-specific bioadhesive particulate systems for oral delivery to the gastrointestinal tract. Adv Drug Del Rev 34: 191-219.
90. Jani P, Halbert GW, Langridge J and Florence AT (1990) Nanoparticle uptake by the rat gastrointestinal mucosa: Quantitation and particle size dependency. J Pharm Pharmacol 42:821-826.
91. Araujo L, Sheppard M, Lobenber R and Kreuter J (1999) Uptake of PMMA nanoparticles from the gastrointestinal tract after oral administration to rats: Modification of the body distribution after suspension in surfactant solutions and in oil vehicles. Int J Pharm 176:209-224.
92. Couvreur P, Lenaerts V, Kante B, Roland M and Speiser P (1980) Oral and parentral administration of insulin associated hydrolysable nanoparticles. Acta Pharm Technol 26:220-222.
93. Delie F and Blanco-Prieto M (2005) Polymeric particulates to improve oral bioavailability of peptide drugs. Molecules 10:65-80.
94. Narayani R (2001) Oral delivery of insulin - making needles needless. Trends Biomater Artif Organs 15:12-16.
95. Sakuma S, Suzuki N, Sudo R, Hiwatari K, Kishida A and Akashi M (2002) Optimized chemical structure of nanoparticles as carriers for oral delivery of salmon calcitonin. Int J Pharm 239:185-195.
96. Damge C, Michel C, Aprahamian M and Couvreur P (1988) New approach for oral administration of insulin with polyalkylcyanoacrylate nanocapsules as drug carrier. Diabetes 37:246-251.
97. Pan Y, Li YJ, Zhao HY, Zheng JM, Xu H, Wei G, Hao JS and Cui FD (2002) Bioadhesive polysaccharide in protein delivery system: Chitosan nanoparticles improve the intestinal absorption of insulin in vivo. Int J Pharm 249:139-147.
98. Damge C, Michel C, Aprahamian M, Couvreur P, Devissaguet J (1990) Nanocapsules as carriers for oral peptide delivery. J Control Rel 13:233-239.
99. Aboubakar M, Couvreur P, Pinto-Alphandary H, Gouritin B, Lacour B, Farinotti R, Puisieux F and Vauthier C (2000) Insulin-loaded nanocapsules for oral administration: In vitro and in vivo investigation. Drug Dev Res 49:109-117.
100. Ramtoola Z (1997) Controlled release biodegradable nanoparticles containing insulin. US Patent No. 5641515.
101. Agnihotri SA, Mallikarjuna NN and Aminabhavi TM (2004) Recent advances on chitosan-based micro- and nanoparticles in drug delivery. J Control Rel 100:5-28.
102. Carino GP, Jacob JS and Mathiowitz E (2000) Nanosphere based oral insulin delivery. J Control Rel 65:261-269.
103. Foss AC, Goto T, Morishita M and Peppas NA (2004) Development of acrylic-based copolymers for oral insulin delivery. Eur J Pharm Biopharm 57:163-169.
104. Lee WK, Park JY, Yang EH, Suh H, Kim SH, Chung DS, Choi K, Yang CW and Park JS (2002) Investigation of the factors influencing the release rates of cyclosporin A-loaded micro- and nanoparticles prepared by high-pressure homogenizer. J Control Rel 84:115-123.
105. Molpeceres L, Aberturas MR and Guzman M (2000) Biodegradable nanoparticles as a delivery system for cyclosporine: Preparation and characterization. J Microencapsul 17:599-614.
106. El-Shabouri MH (2002) Positively charged nanoparticles for improving the oral bioavailability of cyclosporin-A. Int J Pharm 249:101-108.
107. Young TJ, Johnston KP, Pace GW and Mishra AK (2003) Phospholipid-stablized nanoparticles of cyclosporine A by rapid expansion from supercritical to aqueous solution. AAPS PharmSciTech 5:1-16.
108. Wang XQ, Dai JD, Chen Z, Zhang T, Xia GM, Nagai T and Zhang Q (2004) Bioavailability and pharmacokinetics of cyclosporine A-loaded pH-sensitive nanoparticles for oral administration. J Control Rel 97:421-429.
109. Varela MC, Guzman M, Molpeceres J, del Rosario Aberturas M, Rodriguez-Puyol D and Rodriguez-Puyol M (2001) Cyclosporine-loaded polycaprolactone nanoparticles: Immunosuppression and nephrotoxicity in rats. Eur J Pharm Sci 12:471-178.
110. Cho M, Levy R, Pouletty P, Floc’h R and Merle C (1997) Oral cyclosproin formulations, Int Patent WO 97/07787.
111. Chen J, Yang WL, Li G, Qian J, Xue JL, Fu SK and Lu DR (2004) Transfection of mEpo gene to intestinal epithelium in vivo mediated by oral delivery of chitosan-DNA nanoparticles. World J Gastroenterol 10:112-116.
112. Leong K, Okoli G and Hottelano G (2003) Compositions for oral gene therapy and methods of using same. International Patent WO 03/02867 A2.
113. Chang SF, Chang HY, Tong YC, Chen SH, Hsaio FC, Lu SC and Liaw J (2004) Nonionic polymeric micelles for oral gene delivery in vivo. Hum Gene Ther 15:481-493.
114. Roy K, Shau-Ku H, Sampsom H and Leong K (2002) Oral delivery of nucleic acid vaccines by particulate complexes. US Patent 6475995 B1.
115. Roy K, Mao HQ, Huang SK and Leong KW (1999) Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat Med 5:387-391.
116. Kim SY, Doh HJ, Jang MH, Ha YJ, Chung SI and Park HJ (1999) Oral immunization with Helicobacter pylori-loaded poly(D, L-lactide-co-glycolide) nanoparticles. Helicobacter 4:33-39.
117. Pamujula S, Graves RA, Freeman T, Srinivasan V, Bostanian LA, Kishore V and T.K. M (2004) Oral delivery of spray dried PLGA/amifostine nanoparticles. J Pharm Pharmacol 56:1119-1125.
118. Sharma A, Sharma S and Khuller GK (2004) Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis. J Antimicrob Chemother 54:761-766.
119. Allison MC, Cornwall S, Poulter LW, Dhillon AP and Pounder RE (1988) Macrophage heterogeneity in normal colonic mucosa and in inflammatory bowel disease. Gut 29:1531-1538.
120. Seldenrijk CA, Drexhage HA and Meuwissen SGM (1989) Dendritic cells and scavanger macrophage in chronic inflammatory bowel disease. Gut 30:484-491.
121. Probert CS, Chott A, Turner JR, Saubermann LJ, Stevens AC, Bodinaku K, Elson CO, Balk SP and Blumberg RS (1996) Persistent clonal expansions of peripheral blood CD4+ lymphocytes in chronic inflammatory bowel disease. J Immunol 157:3183-3191.
122. Tabata Y, Inoue Y and Ikada Y (1996) Size effect on systemic and mucosal immune responses induced by oral administration of biodegradable microspheres. Vaccine 14:1677-1685.
123. Lamprecht A, Stallmach A, Kawashima Y and Lehr CM (2002) Carrier systems for the treatment of inflammatory bowel disease. Drugs Fut 27:961-971.
124. Zhang H, Alsarra IA and Neau SH (2002) An in vitro evaluation of a chitosan-containing multiparticulate system for macromolecule delivery to the colon. Int J Pharm 239: 197-205.
125. Rodriguez M, Vila-Jato JL and Torres D (1998) Design of a new multiparticulate system for potential site-specific and controlled drug delivery to the colonic region. J Control Rel 55:67-77.
126. Schmidt C and Bodmeier R (1999) Incorporation of polymeric nanoparticles into solid dosage forms. J Control Rel 57:115-125.
127. Refer to presentations and publications at www.fda.gov/nanotechnology.
128. Refer to the technical information posted by Skye Pharma at www.skyepharma.com/solubilization.html.
129. Refer to the technical information posted by Elan at http://www.elan.com/drugdelivery/drug delivery/nanocrystal_technology.asp.
130. Arangoa MA, Campanero MA, Renedo MJ, Ponchel G and Irache JM (2001) Gliadin nanoparticles as carriers for the oral administration of lipophilic drugs. Relationships between bioadhesion and pharmacokinetics. Pharm Res 18:1521-1527.
131. Murakami HK, M.; Takeuchi, H.; Kawashima, Y. (2000) Utilization of poly(DL-lactide-co-glycolide) nanaoparticles for preparation of mini depot tablets by direct compression. J Control Rel 37:29-36.
132. Tobio M, Sanchez A, Vila A, Soriano II, Evora C, Vila-Jato JL and Alonso MJ (2000) The role of PEG on the stability in digestive fluids and in vivo fate of PEG-PLA nanoparticles following oral administration. Coll Surf B Biointerf 18: 315-323.
133. Hillery A, Florence A (1996) The effect of adsorbed poloxamer 188 and 407 surfactants on the intestinal uptake of 60-nm polystyrene particles after oral administration in the rat. Int J Pharm 132:123-130.
134. Sakuma S, Sudo R, Suzuki N, Kikuchi H, Akashi M, Ishida Y and Hayashi M (2002) Behavior of mucoadhesive nanoparticles having hydrophilic polymeric chains in the intestine. J Control Rel 81:281-290.
135. Yoo HP, T. (2004) Biodegradable nanoparticles containing protein-fatty acid complexes for oral delivery of salmon calcitonin. J Pharm Sci 93:488-495.
136. Arbos P, Campanero MA, Arangoa MA and Irache JM (2004) Nanoparticles with specific bioadhesive properties to circumvent the pre-systemic degradation of fluorinated pyrimidines. J Control Rel 96:55-65.
137. Jiao Y, Ubrich N, Marchand-Arvier M, Vigneron C, Hoffman M, Lecompte T and Maincent P (2002) In vitro and in vivo evaluation of oral heparin-loaded polymeric nanoparticles in rabbits. Circulation 105:230-235.
138. Arbos P, Campanero MA, Arangoa MA, Renedo MJ and Irache JM (2003) Influence of the surface characteristics of PVM/MA nanoparticles on their bioadhesive properties. J Control Rel 89:19-30.
139. Barichello JM, Morishita M, Takayama K and Nagai T (1999) Encapsulation of hydrophilic and lipophilic drugs in PLGA nanoparticles by the nanoprecipitation method. Drug Dev Ind Pharm 25:471-476.
140. Molpeceres J, Aberturas MR and Guzman M (2000) Biodegradable nanoparticles as a delivery system for cyclosporine: Preparation and characterization. J Microencapsul 17:599-614.
141. Ubrich N, Schmidt C, Bodmeier R, Hoffman M and Maincent P (2005) Oral evaluation in rabbits of cyclosporin-loaded Eudragit RS or RL nanoparticles. Int J Pharm 288:169-175.
142. Mesiha MS, Sidhom MB and Fasipe B (2005) Oral and subcutaneous absorption of insulin poly(isobutylcyanoacrylate) nanoparticles. Int J Pharm 288:289-293.
143. Pamujula S, Graves RA, Freeman T, Srinivasan V, Bostanian LA, Kishore V and Mandal TK (2004) Oral delivery of spray dried PLGA/amifostine nanoparticles. J Pharm Pharmacol 56:1119-1125.